G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2026

G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

• G-CSF (Granulocyte Colony Stimulating Factors) market size has reached to $9.48 billion in 2025 • Expected to grow to $12.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Rising Prevalence Of Cancer Drives G-CS Market Growth • Market Trend: Advancing Hematopoietic Therapies Through Dimeric Fusion Protein Innovation • North America was the largest region in 2025.

What Is Covered Under G-CSF (Granulocyte Colony Stimulating Factors) Market?

G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumors, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it. The main types of G-CSF (granulocyte colony-stimulating factors) market are lenograstim, filgrastim, Pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablets, capsules, and others and are used in oncological diseases, blood disorders, growth hormone deficiencies, and chronic and autoimmune disorders, and others.

What Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Growth Forecast?

The g-csf (granulocyte colony stimulating factors) market size is expected to see strong growth in the next few years. It will grow to $12.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to launch of novel g-csf products, expansion of biosimilars in emerging markets, increasing use of combination therapies, rising demand for pre-filled syringe formulations, growing investment in supportive care and neutropenia management programs. Major trends in the forecast period include rising demand for biosimilars of g-csf products, increasing adoption of pre-filled syringes and injectable formulations, growth in combination therapies with other growth factors, expansion of g-csf use in oncology and blood disorder treatments, rising awareness of neutropenia management and supportive care.

Global G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types 2) By Product Form: Tablet, Capsule, Other Product Forms 3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications Subsegments: 1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim 2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies 3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim 4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

What Is The Driver Of The G-CSF (Granulocyte Colony Stimulating Factors) Market?

The increasing prevalence of cancer is expected to propel the growth of the G-CSF (granulocyte colony stimulating factor) market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells, which can disrupt normal body functions and lead to death. The rise in prevalence of cancer is fueled by factors such as aging populations, lifestyle changes, and environmental exposures that increase cancer risk. The G-CSF market supports this shift by providing growth factors that stimulate white blood cell production, reducing the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the G-CSF (granulocyte colony stimulating factor) market.

Key Players In The Global G-CSF (Granulocyte Colony Stimulating Factors) Market

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Global G-CSF (Granulocyte Colony Stimulating Factors) Market Trends and Insights

Major companies operating in the G-CSF (granulocyte colony stimulating factor) market are focusing on technological innovation in hematopoietic therapies, such as dimeric fusion protein design to enhance neutrophil production and reduce immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design refers to linking two G-CSF molecules into a single protein to extend half-life and improve receptor activation without PEGylation. For instance, in November 2023, Evive Biotech Inc., a Singapore-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), a long-acting biosimilar G-CSF for reducing the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, stimulates neutrophil production in the bone marrow, accelerating recovery of neutrophil counts. Its key features include long-acting dosing, compatibility with multiple chemotherapy regimens, and a ready-to-use prefilled syringe. It is used for prophylaxis of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care in immunocompromised patients, offering benefits like fewer injections, improved adherence, and better overall patient outcomes.

What Are Latest Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

In August 2025, Intas Pharmaceuticals Ltd., an India-based biotechnology company, acquired the UDENYCA from Coherus BioSciences, Inc. for an undisclosed amount. With this acquisition, Intas Pharmaceuticals and Accord BioPharma seek to solidify their global leadership in pegfilgrastim, broaden their FDA-approved biosimilar offerings, and provide patients with greater access to safe, effective, and flexible treatment options for preventing infections during cancer therapy. Coherus BioSciences Inc. is a US-based, commercial-stage biopharmaceutical company, focused on both biosimilars and innovative immuno-oncology therapies, with a team of industry veterans leveraging deep expertise in biologics development and commercialization.

Regional Insights

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the G-CSF (Granulocyte Colony Stimulating Factors) Market?

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2026?

The g-csf (granulocyte colony stimulating factors) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the g-csf (granulocyte colony stimulating factors) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.